TSE:NWH.UN

Northwest Health Prop Real Est Inv Trust (NWH.UN.TO)

5.66
-0.01 (0.18%)
as of Mar 10, 2026, 8:00:00 pm Market Open.
343 watching
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Northwest Health Prop Real Est Inv Trust (NWH.UN-T) has been undergoing significant transformation under new management, particularly a CEO with experience from Brookfield. The company is in a restructuring phase, focusing on its North American assets while divesting from international operations, which many analysts view as a necessary step due to previous over-leverage. Despite challenges, including increased debt servicing costs and a forced asset sale, the company appears to have stabilized operations. Analysts note a stable yield over 6%, with some optimism surrounding its long-term potential, although many express caution regarding immediate price appreciation. Overall, the company's diverse portfolio of medical assets presents opportunity, but future growth may hinge on its execution of strategic initiatives.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
CNA, CEC
TOP PICK

New CEO came from Brookfield and has turned the company around. Selling assets to concentrate in NA. Healthcare is a growing business. Yield is now over 6%, one of the better yields in the market.

(Analysts’ price target is $6.30)
WAIT

Interesting mix of assets. Medical offices in Canada, hospitals and such in Europe, NZ, and Australia. Took on a lot of debt, paid a big dividend, and then it all didn't work out very well. Management got replaced, new management doing a good job.

Now much leaner. Curtailing footprint and driving synergies. Likes international footprint because of long-dated leases with inflation escalators. Canadian leases are more short-term. "OK" at this price, but not a screaming buy. Rumours of a takeover. You could buy for the dividend, but he'd wait for a pullback. Don't expect much price appreciation.

BUY

As did many companies, had to refinance its debt in 2022, going from 1-2% to 5%. That was a big headwind. Had to do a fire sale on some assets. Now stabilized. NAV is ~$7.50-8 per share. New CEO taking action to realize underlying value of the company. 

A recent Top Pick, so he really likes it. Great entry point. Not a lot of economic sensitivity. Paying down debt, buying back stock and bonds. Yield is ~7%.

WATCH

A turnaround story. Had grown too far, too fast, too much leverage. Now, there's new management. Is a show-me story. Can they sell foreign businesses and focus on North American assets. Expect a lot of churn, but more positive.

DON'T BUY

Lost their way from original Canadian investment model when it went overseas. For a mid-cap stock to be successful, you have to do one thing and do it well. Wouldn't touch it until it exits foreign operations entirely.

TOP PICK

Hospital and medical offices around the globe, very strong assets, some with 10- or 20-year leases. Hit hard in 2022 with higher interest rates on too much debt. Replaced CEO. One of the cheapest REITs on the market. 

Chairman owns about 10% of the stock, just through open-market purchases. He likes management that puts their own $$ in. Yield is 7.10%.

(Analysts’ price target is $5.57)
PAST TOP PICK
(A Top Pick Aug 27/25, Up 3%)

(Note the short timeframe.)  A lower-beta, higher-dividend choice for the summer when risks were higher than usual.

Note that he'll probably be out of this soon, see if it swings up over the next few weeks and then exit.

WATCH

Show-me story. New management tasked with a much-needed overhaul. Quality assets, but in disparate geographies globally. May exit some of them to focus on Canada and US. Earnings growth may be delayed.

TOP PICK

Lower beta, boring for this time of year. Two overlooked sectors in one -- healthcare and REITs. Steady eddy. Should probably hold its own between now and the fall, when he'll probably exit. Collect the dividend, might go up a couple of bucks, better than cash. Decent yield of 7.34%.

(Analysts’ price target is $5.57)
PAST TOP PICK
(A Top Pick Aug 27/24, Down 1%)

It is caught up in the interest rate environment. Pays a 7 1/2% dividend and is in the defensive healthcare space. Has long term leases with rent escalators built in. Debt is down and cash flow up. The payment ratio is very sustainable. This will be the first earnings call for the new CEO.

WATCH

Not very focused geographically, so all those moving parts are hard to maintain. Likes some changes they've made with management and the balance sheet, so he's watching it now. One of largest tenants in Australia has gone bankrupt, which could affect 5-10% of earnings. It's a wait and see.

DON'T BUY

Likes the space. Diversified assets globally. Capital allocation decisions caught up to them, and stock dropped in 2022. Liquidity crunch, management shakeup, new CEO set to retire. Attractive yield is in question. If you want safety, this isn't it.

HOLD
Does dividend cut mean it's now in a good financial spot?

Yes, in much better position today than previously. Management transition. Hard to see it going back to $10 levels anytime soon. Decent job allocating capital (ie. selling assets) to pay down debt. Enough to pay March debentures. Risk/reward not that compelling.

BUY

One of the most attractive REITs on the TSX right now. Coming out of poor fundamental operations where capital allocation was mismanaged. New CEO cut dividend, sold properties. Prepared either way if interest rates fall or rise. Payout ratio will fall closer to 80%. Stock may have fallen recently because that new CEO is retiring next year. Yield is 7.3%, one of the highest out there.

RISKY

Balance sheet's really under pressure, making progress with repairing. Management shakeup, but now the new CEO's leaving in 2025. Lots of heavy work to do. Only for those with high risk tolerance. More compelling opportunities elsewhere.

Showing 1 to 15 of 133 entries

Northwest Health Prop Real Est Inv Trust (NWH.UN.TO) Frequently Asked Questions

What is Northwest Health Prop Real Est Inv Trust stock symbol?

Northwest Health Prop Real Est Inv Trust is a Canadian stock, trading under the symbol NWH.UN.TO (previously NWH.UN-T on Stockchase) on the Toronto Stock Exchange (NWH.UN-CT). It is usually referred to as TSX:NWH.UN or NWH.UN.TO

Is Northwest Health Prop Real Est Inv Trust a buy or a sell?

In the last year, 7 stock analysts issued a Buy, Sell, or Hold rating on NWH.UN.TO (previously NWH.UN-T on Stockchase). 6 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is RISKY. Read the latest stock experts' ratings for Northwest Health Prop Real Est Inv Trust.

Is Northwest Health Prop Real Est Inv Trust a good investment or a top pick?

Northwest Health Prop Real Est Inv Trust was recommended as a Top Pick by Andrew Moffs on 2024-10-31. Read the latest stock experts ratings for Northwest Health Prop Real Est Inv Trust.

Why is Northwest Health Prop Real Est Inv Trust stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Northwest Health Prop Real Est Inv Trust.

Is Northwest Health Prop Real Est Inv Trust worth watching?

Northwest Health Prop Real Est Inv Trust is followed by 343 investors on Stockchase and is a trending stock that is worth watching.

What is Northwest Health Prop Real Est Inv Trust stock price?

On 2026-03-10, Northwest Health Prop Real Est Inv Trust (NWH.UN.TO) stock closed at a price of $5.66.

Star iconStar iconStar iconStar iconStar half icon
4.4(7)
Based on 7 expert opinions: 6 buy 0 hold 1 sell